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Background: Breast cancer affects one in eight UK women during their lifetime: many of these women now
receive adjuvant chemotherapy and hormone therapy. Joint and muscle pains, aches, and stiffness are common
but the natural history, aetiology and impact of these symptoms are unknown. A cohort study of newly diagnosed
women with primary breast cancer was established to explore this. In this paper we present study methods and
sample characteristics, describe participants’ experience of musculoskeletal pain at baseline interview, and explore
its impact on quality of life.
Methods: Women with non-metastatic breast cancer were recruited following primary surgery into a multi-centre
cohort study. They received questionnaires by post five times (baseline, 3, 6 , 9 and 12 months) to investigate
prevalence, severity, location and correlates of musculoskeletal pain, and impact on quality-of-life. Pain was
measured by the Nordic musculoskeletal questionnaire, the Brief Pain Inventory, and MSK-specific questions, and
quality of life by the SF-36 and FACIT scales.
Results: 543 women (mean age 57 years, range 28–87, 64% postmenopausal) were recruited following surgery for
primary breast cancer from breast cancer clinics in eight hospitals. Fifteen per cent of the eligible cohort was
missed; 28% declined to participate. Joint or muscle aches, pains or stiffness were reported by 69% women with
28% specifically reporting joint pain/aches/stiffness. Quality of life, as measured by the FACT-B and adjusted for age,
depression, surgery and analgesic use, is significantly worse in all domains in those with musculoskeletal problems
than those without.
Conclusions: Our findings highlights the importance of a better understanding of these symptoms and their
impact on the lives of women with primary breast cancer so that healthcare professionals are better equipped to
support patients and to provide accurate information to inform treatment decisions. Further papers from this study
will address these issues.
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Breast cancer affects one in eight women during their
lifetime in the United Kingdom [1] and almost two thirds
of newly diagnosed women are now likely to survive for at
least 20 years [2]. This increase in cancer survivorship is
largely due to adjuvant chemotherapy and hormone ther-
apy [3]. Musculoskeletal pain and stiffness are common
complaints following primary breast cancer treatment [4],
but there is little information on the natural history of
these symptoms and their impact on women’s lives over
time. Aromatase inhibitors (AIs), such as anastrozole,
letrozole and exemestane, are the recommended hormone
treatment for postmenopausal women as they have been
shown to be more effective in preventing recurrence than
tamoxifen alone [5]; however, recent clinical reports and
small cohort studies have reported that up to 74% of
patients receiving adjuvant-AI therapy develop pain or
stiffness in their joints [4,6-10]. This non-arthritis
pain/stiffness, or arthralgia, is common in postmeno-
pausal women [11] but a cross-sectional survey of more
than 500 subjects conducted by this group demonstrated
that women with breast cancer had significantly more
musculoskeletal pain than women of a similar age attend-
ing breast screening clinic (62% of breast cancer patients
vs 53% of healthy controls, p = 0.023) [12]. A recent cohort
study supports this finding: 91 women on AIs were com-
pared to a group of postmenopausal women without
breast cancer (n = 177), with women on AIs having more
severe arthralgia at six weeks than women without breast
cancer [13].
The causes of joint and muscle aches/pains/ stiffness
in women with breast cancer are unknown; however,
oestrogen deprivation has been suggested as one pos-
sible cause [9,14,15]. Although oestrogen has no known
effect on articular structures that would protect against
musculoskeletal pain, it is known to influence the in-
flammation pathway and neural processing of nocicep-
tive input [16,17]. Women treated with AIs have an
associated decline in bone mineral density as a result of
low oestrogen levels, which may further exacerbate
musculoskeletal symptoms [18]. There appears to be a
relationship between a shorter time since last menstrual
period and the development of joint pain and stiffness
(arthralgia) after primary breast cancer treatment which
supports this hypothesis [9,19,20]. A recent cohort study,
however, observed that the menopause-like symptoms ex-
perienced by women on AIs were independent of joint
pain development suggesting that reported musculoskel-
etal pain is not due to oestrogen alone [21]. There is also
evidence supporting the development of musculoskeletal
pain following chemotherapy: 87% of a cohort of Canadian
women (n = 82) reported pain as a side effect of taxane
chemotherapy [22-24]. This has not been examined in
large, prospective cohorts nor have the compound effectsof hormone therapy and chemotherapy been explored.
The lack of robust evidence on which adjuvant treatments
are associated with musculoskeletal pain and why means
that women can struggle to make informed judgments
about proposed treatments and may be reluctant to take
up hormone therapy [25] despite its life-lengthening
benefits. Furthermore, severe side effects, arthralgia in
particular, have been shown to be responsible for the
discontinuation of hormone therapy [26-28]. A large,
multi-centre study in the United States found that
nearly a quarter of patients discontinued AI therapy due
to musculoskeletal symptoms [28].
Musculoskeletal pain is an important issue for women
as it has a negative impact on functional ability and
quality-of-life [6,29]. Distress may also be caused if women
are unable to differentiate between pain due to metastatic
bone cancer or to treatment-aggravated musculoskeletal
pain [30]. This new musculoskeletal pain is often reported
as being moderate or severe and daily tasks cannot be
conducted without the use of pain-killers [6,31]. Recent
literature on AI-related arthralgia have identified the
hands/wrists and feet/ankles as the most likely locations
for joint pain and that pain in these joints has a very high
impact on functional ability [6,11,19,26]. Information on
musculoskeletal pain following breast cancer treatment,
however, has come from retrospective analyses of large
clinical trials where pain was not the focus; in addition to
questions about its relationship to adjuvant therapies, the
nature, duration and impact of the pain has not been
established. We have therefore conducted a cohort study
to establish the natural history of joint and muscle aches,
pains and stiffness over time in women being treated for
early breast cancer; to explore their impact on quality
of life and functional ability; and to explore differences
in joint and muscle aches, pains and stiffness over time
between women who received different adjuvant treat-
ments. In this paper we present the study methods and
sample characteristics from baseline interviews, including
hypothesised causes of musculoskeletal pain: after primary
surgery but before adjuvant treatment. We describe par-
ticipants’ experience of musculoskeletal pain at baseline
interview and investigate the impact of surgery. We ex-
plore cancer-related quality of life, and the impact of
musculoskeletal pain on this.
Methods
The Joint Aches Cohort Study (JACS) is a prospective,
multicentre cohort study studying women with non-
metastatic breast cancer for one year following their pri-
mary surgery. Research ethics approval was obtained
from the National Research Ethics Service, Isle of
Wight, Portsmouth and South East Hampshire Research
Ethics Committee, and written consent was obtained
from each participant.
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Women diagnosed with primary breast cancer, either
invasive carcinoma or ductal carcinoma in situ (DCIS),
at one of 15 NHS hospitals across the south of England
and Wales were eligible to participate in the JACS study.
Recruitment to the prospective cohort commenced in
January 2010 and finished in December 2011 when the
target sample size of 500 patients was reached. Inclusion
criteria were: a histologically confirmed diagnosis of breast
cancer; no previous diagnosis of cancer (other than non-
melanomatous skin cancer); at least 18 years of age; no
evidence of metastatic disease; no neoadjuvant treatment;
able to complete written records in English; female. Men
were excluded from the study as their numbers were likely
to be extremely low. A dedicated research nurse from each
hospital recruited women in clinic following their primary
surgery. All recruited participants were followed for a
period of one year from consent.
Sample size calculations
Recruiting over a 15-month period, as originally proposed,
we estimated 100 patients with DCIS and 900 women with
invasive breast cancer would present at participating
clinics, with a recruitment rate of 50%. Approximately
one-third of the 450 invasive breast cancer patients
were estimated to be in each of the three treatment
groups: 150 receiving chemotherapy only, 150 receiving
hormone therapy only, and 150 receiving both chemo-
therapy and hormone therapy. The 50 recruited DCIS
patients would form the comparison group, together
with any patients with invasive cancer not receiving any
adjuvant systemic therapy, as they were likely to have
no further treatment. These numbers would enable us
to detect a difference in prevalence of musculoskeletal
pain of between 70% and 86% with 89% power.
Data collection
Questionnaires were sent, via post, to all participants at
baseline, three months, six months, nine months, and
twelve months; and returned directly to the researchers
using a FREEPOST envelope.
Two standardised measures of pain were used to as-
certain the prevalence of musculoskeletal pain and the
impact of this pain on daily life: the Nordic question-
naire, which gives data on 12 specified sites of the body
[32] and the Brief Pain Inventory (BPI) [33]. To assess
quality-of-life and functional status the FACT-G/FACT-
B/FACT-ES [34,35] and the SF-36 [36] were used. Data
on demographics, as well as co-existing conditions and
potential confounders were also collected. These in-
cluded presence of lymphoedema, weight, ACE inhibitor
usage, use of Vitamin D and Calcium supplements. Add-
itional questions included analgesia use; use of other
medications; vitamins B6, B12, C,D and E; glucosamine;fish oil; evening primrose oil; any other complementary
or herbal remedies; any other complementary therapies,
including yoga, acupuncture, tai chi, aromatherapy, hom-
eopathy and reflexology. An additional short questionnaire
was sent to participants in November 2012 to obtain ac-
curate information on current menopause status, the time
since last menstrual period (less than 5 years, between 5 &
10 years, greater than 10 years), and previous use of hor-
mone replacement therapy (HRT). Clinical information
was obtained from the hospital notes including: primary
surgery; adjuvant chemotherapy regimens; radiotherapy
details; and the type(s) of hormone therapy prescribed.
Previous diagnoses of arthritis, fibromyalgia, and meno-
pause status were not collected as this is not accurately
reported in the oncology medical notes.
Statistical analyses
Descriptive statistics were used to compare the JACS
sample with regional and national breast cancer statistics
obtained from Public Health England Knowledge and
Intelligence Team (South West). Further descriptive sta-
tistics were used to describe the sample, baseline pain
levels, and to explore factors that might potentially con-
found the relationship between musculoskeletal pain
and systemic primary breast cancer treatment. Forward,
step-wise, multi-level logistic regression analysis was
used to explain the effect of baseline joint and muscle
aches and pains on quality-of-life. Further analyses ex-
plored the effect and type of surgery on baseline pain
levels, specifically pain in the affected chest and upper
arm regions as described by the BPI questionnaire. The
data were analysed using STATA software (Version 12,
SE). Data are presented with reference to the STROBE
statement for cohort studies [37].
Results
The data proved to be clustered by site, therefore seven
sites that recruited fewer than 20 women were removed
from all analyses, bringing the total sample down from
578 to 543 women. The clustering effect of site was in-
cluded in all multi-level models. Research nurses on
each site had been asked to keep records on the number
of eligible patients missed and/or declined. These data
were not available for two of the recruiting hospital
sites, bringing the total number of eligible patients re-
cruited to 455. The recruitment rate from the six
remaining hospitals ranged from 37% to 79% of the eli-
gible cohort. Overall, the 455 women recruited from
these hospitals represent 57% of women eligible for the
study. A total of 116 (15%) eligible women were missed
by the recruiting nurses and a further 28% declined to
participate (n = 225, Figure 1). Three patients were in-
eligible as it was later discovered that they had received
a previous cancer diagnosis. It was originally intended
Figure 1 Recruitment flowchart. *Full eligibility data is not available for two hospitals due to long-term research nurse absence and incomplete
screening logs. The numbers for these hospitals are excluded from the flowchart.
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those women undergoing adjuvant therapy; however, it
was found that women with DCIS were frequently given
adjuvant therapy and so the data on these subjects have
not been presented separately.
Description of the sample
A total of 543 women were included in the JACS sample.
Ninety-eight percent of participants returned the baseline
questionnaire (n = 535) and full medical details are avail-
able for 99% of the recruited women. Age ranged from 28
to 87 years, with a mean age of 57 (Table 1). Most women
were either married or in a long-term relationship (78%)
and 45% were employed at least part-time. More than half
(55%) were less than 60 years of age, 98% were of a White
ethnic group, and 41% came from the two least deprived
Index of Multiple Deprivation (IMD) quintiles.
All the women in the cohort had primary breast can-
cer surgery. Wide local excision (WLE) was the most
common surgery (67%) and 33% of women had a single
or double mastectomy (Mx). Sentinel lymph node biop-
sies (SLNB) were undertaken in 56% of women and 30%
had axillary node clearance (ANC) (Table 2). At the time
of surgery, 45% of the sample was scheduled to have adju-
vant chemotherapy, of whom 43% were scheduled to have
taxane-containing chemotherapy (Table 2). Most women
were scheduled to commence adjuvant hormone therapy;
28% of the women were scheduled to take an initial AI
therapy while 43% were scheduled to start tamoxifen. The
hormone therapy prescribed for post-menopausal women
varied considerably by site: for example, one hospital
prescribed tamoxifen in preference to AIs to 78% of
post-menopausal women whilst others prescribed AIs
as a first-line treatment to 75% of women.
Only 37% of women reported no other long-term
health conditions (n = 195). Hypertension was reported
by 26% of women. Over 50% of the sample (n = 245) was
classed as being overweight or obese (BMI > 25) (Table 3).
The majority of the women were post-menopausal (64%)and 33% reported previous HRT use, which may related to
the number reporting a hysterectomy (n = 85). Nearly a
quarter of our sample reported a diagnosis of an arthritis,
joint or muscle related condition (rheumatoid arthritis,
osteoarthritis, other arthritis, or fibromyalgia) (Table 3).
Information was also collected on other causes of
musculoskeletal pain, to enable their effects to be con-
trolled for in later analysis when exploring the effects of
adjuvant treatment. These included weight, a history of
joint pain or arthritis, other long term conditions and
some medications (including ACE inhibitors, gastric acid
reducers, quinolones, tibolones, and zoledronic acid)
[38] have all been monitored in this sample (Table 3).
Twenty percent of women in this study were on medica-
tions known to cause arthralgia (n = 105). Menopause
status and the time since their last menstrual period
were monitored due to the believed role of oestrogen
deprivation in the development of musculoskeletal pain.
Nearly 80% of the JACS cohort were peri or post-
menopausal with only 23% of women reporting their last
menstrual period within the previous five years (Table 3).
Some studies have also linked Vitamin D and other sea-
sonal effects as having a significant role in joint pain devel-
opment in women with breast cancer [31,39-41]. Only 9%
of the cohort reported taking an osteo-enhancing supple-
ment (defined as Vitamin D, Calcium, or Glucosamine) at
baseline; fewer than 20 women reported a daily Vitamin D
supplement.
Pain prevalence
The Nordic Musculoskeletal questionnaire and the BPI
both use broad definitions of pain; the Nordic question-
naire includes any ‘ache, pain, stiffness, discomfort or
numbness’ and the BPI asks: ‘most of us have had pain
from time to time (such as minor headaches, sprains
and toothache). Have you had pain other than these
everyday kinds of pain today’. We, therefore, added to
the Nordic questionnaire six yes/no questions as to
whether the respondent had any joint pain/joint aches/
Table 1 Sample demographics
Number1 (%) South West and Oxford Cancer Registry
Areas, 2009–20112 (%)
England, 2009–2010 (%)2
Age group
<40 31 (6%) 285 (55%) 10,535 (40%) 33,885 (41%)
40-49 100 (19%)
50-59 154 (30%)
60-69 170 (33%) 237 (45%) 15,653 (60%) 47,901 (59%)
≥70 67 (13%)
Ethnicity
White 510 (98%) Information not available 78,075 (95%)
Non-white (Asian/Chinese/Mixed) 9 (2%) 3,711 (5%)
Marital status
Married/Long-term relationship 412 (78%) Information not available Information not available
Single/Divorced/Widowed 113 (22%)
Socio-economic group
Employers & managers 57 (11%) Information not available Information not available
Professionals 64 (12%)
Intermediate non-manual 137 (26%)
Junior non-manual 123 (23%)
Manual (skilled & unskilled) 40 (8%)
Other 45 (8%)
Not known 67 (13%)
Current employment status
Employed (full-time) 131 (25%) Information not available Information not available
Employed (part-time) 122 (23%)
Homemaker 48 (9%)
Unemployed 16 (3%)
Retired 182 (35%)
Other 27 (5%)
Index of multiple deprivation (IMD) quintiles3
1 (Most deprived) 46 (11%) 7,373 (28%) Information not available
2 105 (25%) 7,091 (27%)
3 105 (25%) 6,071 (23%)
4 105 (25%) 4,118 (16%)
5 (Least deprived) 70 (16%) 1,535 (6%)
1Where numbers do not equal 543 missing data are present.
2Data supplied by Public Health England Knowledge and Intelligence Team (South West).
3IMD Quintile data are only comparable within England – patients recruited in Wales were excluded from these calculations (n = 29).
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in the last seven days. These questions were compared
to the initial BPI pain question: 53% of the sample re-
ported pain in both instruments but a further 47% iden-
tified having musculoskeletal pain in our additional
questions that was not recorded using the BPI question-
naire. This difference may be due to the time span of the
questions: our additional questions ask about musculo-
skeletal pain in the previous seven days whilst the BPIquestionnaire focusses on pain in the current 24 hour
period.
Nearly 70% of women report musculoskeletal pain,
including joint or muscle pain, aches, or stiffness, in
the previous seven days in the questions added to the
Nordic questionnaire (n = 391; 69%; 95% CI 65%, 73%),
while only 28% (n = 146; 95% CI 24%, 32%) report joint
aches/pains/stiffness. The BPI questionnaire asks par-
ticipants to identify the location of the greatest source
Table 2 Surgery and planned breast cancer treatment
Number (%)
Surgery type
Mastectomy 15 (3%)
Mastectomy + sentinel node biopsy 69 (13%)
Mastectomy + axillary clearance 95 (18%)
Wide local excision (WLE) 63 (12%)
WLE + sentinel node biopsy 230 (43%)
WLE + axillary clearance 68 (13%)
Planned cancer treatment
No further systemic treatment 82 (16%)
Aromatase inhibitor only 95 (18%)
Tamoxifen only 117 (22%)
Chemotherapy only 72 (14%)
of which taxane chemotherapy – 37 (51%)
Aromatase inhibitor + chemotherapy 52 (10%)
of which taxane chemotherapy – 16 (31%)
Tamoxifen + chemotherapy 107 (20%)
of which taxane chemotherapy – 51 (48%)
Table 3 Medical characteristics of the sample
Number (%)
BMI
Underweight (BMI <18) 7 (1%)
Health weight (BMI 19–25) 235 (48%)
Overweight (BMI 26–29) 120 (25%)
Obese (BMI ≥30) 125 (26%)
Menopause status1
Pre-menopausal 45 (10%)
Peri-menopausal 56 (13%)
Post-menopausal 277 (64%)
Patient unsure 53 (12%)
Time since last menstrual period2
<5 years 76 (23%)
5-10 years 72 (22%)
>10 years 185 (56%)
Previous HRT use
Yes 144 (33%)
Musculoskeletal diagnosis at baseline3
Osteoarthritis 73 (14%)
Rheumatoid arthritis 16 (3%)
Fibromyalgia 7 (1%)
Other arthritis 33 (6%)
Taking other medications known to cause joint pain
(ace inhibitors, proton pump inhibitors, quinolones, tibolones, zoledronic
acid, bisphosphonates, angiotensin-II receptor antagonists, etc.)
Yes 105 (20%)
Osteo-enhancing supplements3
Vitamin D 16 (3%)
Calcium 45 (8%)
Glucosamine 55 (10%)
1Menopause status as defined by the patient.
2Does not include pre-menopausal women or women with unknown status.
3Percentages are % of total cohort and will not sum to 100%.
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tify all other pain locations [33]. Most of the women
completing the baseline questionnaire did not specify a
greatest pain location, but the lower back was identi-
fied as the most frequently cited ‘area that hurts the
most’ (13%). On the Nordic musculoskeletal question-
naire, the most commonly reported pain sites over the
previous 12 months included: lower back pain (50%);
pain in one or both knees (41%); and pain in their hips/
thighs/buttocks (31%, Figure 2). In the 12 months pre-
ceding primary breast cancer surgery, 26% of women
report right wrist or hand pain and 20% report left
hand/wrist pain on the Nordic Musculoskeletal ques-
tionnaire; fewer than 5 women identified these sites as
the location of greatest pain on the BPI questionnaire.
Women were recruited to the JACS study immediately
following primary breast cancer surgery, which offers an
opportunity to examine how pain changes in the weeks
following surgery. The following analyses excluded women
who completed the baseline questionnaire prior to surgery
(n = 21), more than 90 days after surgery (n = 11), and
those with no identified surgery date (n = 21). In the
remaining 491 women, 70% reported joint or muscle
aches/pains/stiffness in the previous 7 days. One in three
(35%) of women reported pain in the shoulder, chest wall,
or underarm on the surgical side. This is the type of
pain than can likely be attributed to surgical interven-
tion (95% CI 29%, 41%). More women who had a mast-
ectomy reported this type of pain (48%) compared with
those receiving a WLE (27%, p = 0.002). The women
most likely to be reporting surgical pain had surgery inthe previous 30 days (48%) but there was no difference
in pain levels between women 31–60 days post-surgery
and those 61–90 days post-surgery. Over-the-counter
(OTC) pain medication usage also varied over time (p =
0.002) with 49% of women with surgery in the previous
30 days reporting OTC pain relief usage, 33% of those
with surgery in the previous 31–60 days, and 48% with
surgery in the previous 61–90 days.
Relationship between musculoskeletal pain and quality
of life
Baseline pain scores from the BPI questionnaire, SF-36
quality-of-life domain scores, and the FACIT scores are
presented in Table 4; these scores are further subdivided
by those that responded ‘yes’ to any of the questions
Figure 2 Reported pain in previous 12 months as identified in the Nordic Musculoskeletal questionnaire.
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of the following in the previous seven days: joint pain;
joint aches; joint stiffness; muscle aches; muscle pain; or
muscle stiffness). Baseline musculoskeletal pain, as de-
fined from our additional questions, was associated with
significantly worse quality of life in all domains of the
SF-36 and all the FACIT domains, other than social and
emotional well-being.Table 4 Pain and quality of life
Total cohort Musculoskeletal p
mean (SD) mean (SD)
Brief pain inventory (BPI) scores
Pain severity 3.44 (1.79) 3.58 (1.79)
Pain interference 2.87 (2.31) 3.09 (2.33)
SF-36 domains
Physical functioning 74.00 (25.80) 67.82 (27.10)
Role - physical 37.93 (44.21) 31.92 (42.35)
Bodily pain 60.68 (26.30) 55.01 (25.36)
General health 69.44 (19.00) 66.25 (19.88)
Vitality 53.53 (20.60) 49.53 (20.56)
Social functioning 64.22 (25.88) 60.31 (25.71)
Role - emotional 61.17 (43.54) 56.82 (43.92)
Mental health 69.35 (16.96) 67.93 (16.92)
FACT scores
Physical well-being 21.69 (5.08) 20.79 (5.27)
Social well-being 24.40 (4.48) 24.30 (4.46)
Emotional well-being 18.50 (4.14) 18.33 (4.12)
Functional well-being 18.94 (6.35) 18.26 (6.33)
FACT-G total score 81.25 (15.07) 79.31 (15.45)
FACT-B total score 104.27 (19.42) 101.72 (20.12)
FACT-ES total score 166.84 (25.69) 162.30 (26.53)
*Musculoskeletal pain as defined by a ‘yes’ answer to at least one of our six questio
describes all types of pain in the previous 24 hours; both measures are on a scale o
daily life. The SF-36 domains are on a scale of 0–100, with a high score indicating a
well-being subscales are on a scale of 0–28; the emotional well-being sub-scale ran
FACT-ES 0–220; higher scores represent a better QoL.A further multi-level linear regression analysis looking
at the FACT-B total score and baseline pain was con-
ducted; the final model included 480 women (Table 5).
The results were adjusted for site (clustering), age, a
diagnosis of fibromyalgia, previous diagnosis of depres-
sion, axillary node clearance vs sentinel lymph node bi-
opsy, opioid painkiller usage, and OTC painkiller usage.
Time since surgery and mastectomy vs wide local excisionain* No musculoskeletal pain t-test pain vs no pain
mean (SD)
2.64 (1.60) p = 0.006
1.55 (1.62) p = 0.05
87.20 (16.61) p < 0.001
50.75 (45.54) p < 0.001
72.33 (24.32) p < 0.001
76.21 (14.89) p < 0.001
61.99 (17.91) p < 0.001
72.44 (24.65) p < 0.001
69.53 (41.44) p = 0.003
72.34 (16.56) p = 0.006
23.68 (4.02) p < 0.001
24.54 (4.35) p = 0.98
18.89 (4.14) p = 0.17
20.50 (6.13) p < 0.001
85.51 (13.38) p < 0.001
109.83 (16.77) p < 0.001
176.58 (20.97) p < 0.001
ns added to the Nordic Musculoskeletal questionnaire. The Brief Pain Inventory
f 0–10, with 10 being the most severe pain or pain that most interferes with
more favourable health state. The FACIT physical, social, and functional
ges from 0–24; the FACT-G total score ranges from 0–108, FACT-B 0–144,
Table 5 Linear regression model FACT-B total score and
musculoskeletal pain
Change in mean
FACT-B score
95% CI p-value1
Baseline constant 106.01 96.62, 115.41 p < 0.001
Report musculoskeletal pain −5.05 −8.78, −1.33 p = 0.008
Age +0.19 +0.03, +0.34 p = 0.017
History of fibromyalgia −16.95 −31.40, −2.49 p = 0.022
History of depression −8.44 −13.36, −3.52 p = 0.001
Surgery: sentinel
node biopsy
−9.49 −13.30, −5.68 p < 0.001
Surgery: axillary clearance −4.82 −9.62, −0.03 p = 0.049
Current opioid painkiller use −9.01 −13.65, −4.36 p < 0.001
Current OTC painkiller use −4.30 −7.73, −0.87 p = 0.014
Hospital recruitment site −0.09 −0.59, +0.41 p = 0.721
1Overall Likelihood ratio estimate for the model, p = 0.0038.
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total score was reduced by 5 points (95% CI −8.95, −1.76)
in women with musculoskeletal pain, as defined by our
addition to the Nordic Musculokeletal questionnaire, after
adjusting for all the confounding factors (p = 0.0038).
Discussion
This paper presents the first findings from a large pro-
spective multi-centre cohort study to establish the natural
history of joint and muscle aches, pains and stiffness over
time in women being treated for early breast cancer; to ex-
plore their impact on quality of life and functional ability;
and to explore differences in joint and muscle aches, pains
and stiffness over time between women who received dif-
ferent adjuvant treatments. It demonstrates the success of
the study in recruiting over 500 women after primary
breast cancer treatment and before adjuvant cancer treat-
ment, describes methods and sample characteristics, and
presents findings on the prevalence of musculoskeletal
pain, the impact on it of breast cancer surgery, and the
effect of these pains on quality of life.
Nearly three quarters of women (69%) reported joint
or muscle pain, aches or stiffness after primary cancer
surgery but before adjuvant therapy. This is a similar
proportion to that reported in our group’s previous
cross-sectional research (62%) [12]. When only questions
on joint pains, aches or stiffness were included in the
current study this dropped to 28%. We used questions
specific to musculoskeletal pain, aches and stiffness which
produced higher musculoskeletal pain prevalence figures
than the Brief Pain Inventory, used in other studies [20],
which investigates general pain experience rather than fo-
cusing on specific sites. By exploring the sites and preva-
lence of pain attributed to primary breast cancer surgery
we were able to establish that this does not account for
the high rates of musculoskeletal pain reports in womenwith breast cancer. Validation of our pain data is, however,
provided by the fact that the pain reports after surgery are
as might be expected with, for example, more pain in the
arm and shoulder of the affected side, less pain with time,
and more pain after a mastectomy than a WLE.
Our results show the importance of understanding
more about the natural history, aetiology and treatment
of musculoskeletal pain in women with breast cancer:
even in the midst of the emotional turmoil of breast
cancer diagnosis, recent surgery and consideration of ad-
juvant therapies, musculoskeletal pain still had a statisti-
cally significant negative association with quality of life.
Women who reported this pain reported lower physical
functioning, general health, vitality and mental health on
the SF-36, a general measure of health-related quality
of life; they reported more impact on their physical and
emotional roles and had more bodily pain. This was
also reflected on the FACT-G and B, cancer-focused
quality-of-life scales, where women with these pains
again reported lower quality of life. We used multi-
level, multi-variate analysis to control for clustering
and the effect of confounding variables such as time
since surgery, use of analgesia, depression and age: the
negative impact of these pains on quality-of-life remains.
Further findings from our cohort study will help ensure
these symptoms can be effectively addressed and their
impact on quality of life alleviated.
Our study has limitations. Our sample are younger
than would be expected from regional and national data,
with 55% less than 60 years of age compared with 40%
of breast cancer diagnoses in the South West and Oxford
Cancer Registry areas and 41% of breast cancer diagnoses
in England. They are also from more affluent backgrounds
as we have oversampled from the two least deprived Index
of Multiple Deprivation (IMD) quintiles. These are not
uncommon biases in research samples, and, importantly
we did not exclude older women, with women aged 70 or
above comprising 13% of our sample. We were able to re-
cruit 57% of our target population, with other eligible
women either being missed by research nurses in busy
breast cancer clinics or declining to take part. This may
have introduced other, unknown, biases into the study.
Conclusions
In conclusion, musculoskeletal pain is a common prob-
lem following primary breast cancer treatment, but
there is little information on the natural history of this
symptom and its impact on women’s lives over time.
This cohort study of 543 women has been established to
explore the natural history of joint and muscle aches,
pains and stiffness, their impact on quality of life and to
begin to explore how these differ between different treat-
ment groups. In this paper we demonstrate the successful
establishment of the cohort and describe study methods
Fenlon et al. BMC Cancer 2014, 14:467 Page 9 of 10
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musculoskeletal pain and joint pain in women after pri-
mary breast cancer and before adjuvant therapy, and dem-
onstrate its negative association with quality of life. This
highlights the importance of a better understanding of
these symptoms and their impact on the lives of women
with primary breast cancer so that healthcare professionals
are better equipped to support patients and to provide ac-
curate information to inform treatment decisions. Further
papers from this study will address these issues.
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